版本:
中国

BRIEF-Positive results from Replicel's RCS-01 phase I skin trial are the Company's most compelling to date

April 4 Replicel Life Sciences Inc

* Positive results from Replicel's RCS-01 phase I skin trial are the company's most compelling to date

* Interim trial results lead researchers to conclude that injection of RCS-01 is not only very safe, but also has potential to reverse effects of aging skin Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐